Grifols (GRFS) Profit After Tax (2010 - 2020)
Grifols' (GRFS) quarterly Profit After Tax came in at $224.7 million in Q1 2020, up 72.98% YoY from $129.9 million in Q2 2019, and down 54.53% on a QoQ basis from $494.1 million in Q4 2019.
Grifols (GRFS) Profit After Tax (2010 - 2020) Analysis & Trends
Grifols (GRFS) has 11 years of Profit After Tax data on file, last reported at $224.7 million in Q1 2020.
- Quarterly Profit After Tax rose 72.98% year-over-year to $224.7 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $1.4 billion (up 31.95% YoY) and the FY2025 annual result came in at $467.9 million, up 7589.52% from the prior year.
- Profit After Tax retreated to $224.7 million in Q1 2020, from $494.1 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $532.4 million in Q4 2018 to a low of $129.9 million in Q1 2019.
- A 5-year average of $263.1 million and a median of $175.5 million in 2018 frame the typical range for Profit After Tax.
- The widest YoY moves for Profit After Tax: up 235.64% in 2017, down 62.64% in 2017.
- Tracing GRFS's Profit After Tax over 5 years: stood at $151.1 million in 2016, then jumped by 235.64% to $507.2 million in 2017, then rose by 4.99% to $532.4 million in 2018, then decreased by 7.2% to $494.1 million in 2019, then plunged by 54.53% to $224.7 million in 2020.
- The last three Profit After Tax figures came in at $224.7 million (Q1 2020), $494.1 million (Q4 2019), and $129.9 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -248.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 224.70 Mn |
| Dec 31, 2019 | 494.12 Mn |
| Mar 31, 2019 | 129.89 Mn |
| Dec 31, 2018 | 532.45 Mn |
| Jun 30, 2018 | 208.87 Mn |
| Mar 31, 2018 | 175.52 Mn |
| Dec 31, 2017 | 507.16 Mn |
| Jun 30, 2017 | 157.93 Mn |
| Mar 31, 2017 | 142.48 Mn |
| Dec 31, 2016 | 151.10 Mn |
| Sep 30, 2016 | 157.85 Mn |
| Jun 30, 2016 | 157.35 Mn |
| Mar 31, 2016 | 381.34 Mn |
| Dec 31, 2015 | 143.52 Mn |
| Sep 30, 2015 | 155.63 Mn |
| Jun 30, 2015 | 146.72 Mn |
| Mar 31, 2015 | 144.42 Mn |
| Dec 31, 2014 | 163.23 Mn |
| Sep 30, 2014 | 150.66 Mn |
| Jun 30, 2014 | 141,763.74 |